The Role of Cell-Free Circulating DNA in the Diagnosis and Prognosis of Breast Cancer

Cancer is the leading cause of death worldwide. Despite significant advances in cancer treatment, morbidity and mortality rates remain high. Tumor heterogeneity, particularly intertumoral a major therapy failure, underpinning tumor treatment problems variety available therapeutic strategies, including molecularly targeted therapies. Recent massively parallel sequencing digital genomic techniques suggest that cell-free circulating DNA (ctDNA) can be used as “liquid biopsy.” In case breast cancer, ctDNA found plasma to non-invasively scan genomes assess burden.